The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults

Chauhan, Pushpinder S; Mahajan, Vikram K.; Mehta, Karaninder S; Rawat, Ritu; Sharma, Vikas

doi:10.4103/idoj.idoj_142_18

Cited by 27 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case (5.2%) showed no response. In a study by Chauhan et al .,[ 8 ] 42 (82.4%) cases showed complete clearance of warts and nine (17.6%) patients showed a good or unsatisfactory response with the MMR vaccine.…”

Section: Discussionmentioning

confidence: 99%

Intralesional Measles, Mumps and Rubella Vaccine Versus Formic Acid Puncture in the Treatment of Common Warts: A Prospective Randomised Study

D'Souza,

Hundi,

Dandekeri

et al. 2023

Indian Journal of Dermatology

View full text Add to dashboard Cite

Context: Many therapeutic modalities have been reported for the treatment of warts: a common bothersome condition; however, no single treatment is completely effective. Aims: This study aimed to evaluate the efficacy and safety of intralesional injection of measles, mumps and rubella (MMR) vaccine and to compare its efficacy with 85% formic acid puncture for common warts. Settings and Design: This was a prospective comparative study. Methods and Material: A total of 60 patients, divided into two groups, were included in the study. Group A received an intralesional MMR vaccine of 0.3 ml per lesion, and group B received 85% formic acid puncture into each lesion with a maximum of 10 warts treated in each case. Five sessions were conducted every 2 weeks in each case with a follow-up period of 3 months to check for recurrence. Statistical Analysis Used: The Chi-square test, Fisher's test and t -test were used for statistical analysis. A P-value <0.05 was considered statistically significant. Results: In group A, the complete response was observed in 62.5%, partial response in 8% and no response in 4.1% of patients. In group B, the complete response was observed in 31.8%, partial response in 63.6% and no response in 4.5% of patients. The difference in cure rates was found to be statistically significant with a P value of 0.031. No recurrence was observed in both groups in the follow-up period. Conclusions: Immunotherapy by intralesional MMR vaccine is a simple, well-tolerated, effective and cost–benefit modality for the treatment of warts and showed a statistically significant cure rate than formic acid therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Intralesional Measles, Mumps and Rubella Vaccine Versus Formic Acid Puncture in the Treatment of Common Warts: A Prospective Randomised Study

D'Souza,

Hundi,

Dandekeri

et al. 2023

Indian Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Intralesional MMR vaccine can be given in doses of 0.1-0.5 ml which are given at 2-week intervals for a maximum of 5 doses. In a study conducted by Pushpinder et al in 2019 stated that in 51 cases of AGWs who were given 5 doses of MMR immunotherapy, 98% of warts had regressed and 82.4% experienced complete clearance [72] .…”

Section: Who Should Have Bcgmentioning

confidence: 99%

The role of intralesional immunotherapy in Condyloma Acuminata

Lita Setyowatie,

Putri Mulia Bela Grania Hasibuan

2023

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Intralesional immunotherapy is one of the immunotherapy modalities that can be given to patients with condyloma acuminata (CA) with a high success rate both in inhibiting progression and preventing recurrence of genital warts. Intralesional immunotherapy regimens that are currently being studied are the use of vaccines and cytokines. Some of the antigens studied for use as therapy in genital warts include Candida albicans, measles, mumps and rubella (MMR), and Tuberculin/Purified Protein Derivate (PPD), Mycobacterium w, and Bacille Calmette-Guerin (BCG). Vaccines and cytokines work by inducing a delayed-type hypersensitivity response to warts tissue, both through cellular and humoral immune responses, mediated by CD8+ T lymphocytes, CD4+ T lymphocytes, B lymphocytes and regulatory T cells so that this can eliminate HPV virus infection in CA. This literature review aims to provide an understanding of the use of intralesional immunotherapy as an effective alternative therapy in CA.

show abstract

“…Various systemic immunotherapies like intralesional vaccines (BCG vaccine, measles, mumps, rubella virus or MMR vaccine, and Mycobacterium indicus pranii‐MIP) and antiproliferative agents (Vitamin D) have been tried for the treatment of common warts with promising results 8,12–21 …”

Section: Introductionmentioning

confidence: 99%

“…11 Various systemic immunotherapies like intralesional vaccines (BCG vaccine, measles, mumps, rubella virus or MMR vaccine, and Mycobacterium indicus pranii-MIP) and antiproliferative agents (Vitamin D) have been tried for the treatment of common warts with promising results. 8,[12][13][14][15][16][17][18][19][20][21] Their mechanism is based on the local stimulation of cellmediated and humoral immunity using different antigens to clear HPV and the host's infected cells. 22,23 However, selection among existing immunotherapeutic modalities remains challenging as none of them have proven 100% efficacious.…”

Section: Introductionmentioning

confidence: 99%

A prospective randomized controlled study of Mycobacterium Indicus Pranii vaccine, Measles Mumps Rubella vaccine and Vitamin D3 in extragenital cutaneous warts

Lahoria

Singh

Bhardwaj

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Participants: Two hundred patients. Methods: The intervention administered in the groups were normal saline (A), vitamin D 3 (B), MIP (C), and MMR (D). The injections were given into the largest wart at 2-weekly intervals until complete clearance or for a maximum of seven sittings. Posttreatment clearance of the injected wart and the distant wart was compared on the basis of change in wart number, percentage clearance, and mean time to complete clearance. Side effects were recorded.Results: A total of 197 patients were recruited. The mean percentage improvement in the injected and non-injected warts was 68.4% and 66.8%, respectively. Intention to treat analysis (ITT) showed that complete clearance of lesions in injected wart occurred in placebo, vit D 3 , MMR, and MIP arms in 64%, 66%, 58%, and 55% patients, respectively (p > 0.05), while in the non-injected warts in 62%, 64%, 52%, and 53%, respectively (p > 0.05). The mean time to achieve complete clearance of wart was fastest in MIP at 7.1 weeks followed by MMR at 7.2 weeks, VIT D 3 at 7.4 weeks and in placebo group 7.8 weeks (p > 0.05). Side effects noted were fever, pain, erythema, and swelling which was highest in VIT D 3 group (p < 0.05). Conclusion:The efficacy of immunotherapies was comparable to placebo with minimal side effects.

show abstract

The efficacy and safety of intralesional immunotherapy with measles, mumps, rubella virus vaccine for the treatment of common warts in adults

Cited by 27 publications

References 15 publications

Intralesional Measles, Mumps and Rubella Vaccine Versus Formic Acid Puncture in the Treatment of Common Warts: A Prospective Randomised Study

Intralesional Measles, Mumps and Rubella Vaccine Versus Formic Acid Puncture in the Treatment of Common Warts: A Prospective Randomised Study

The role of intralesional immunotherapy in Condyloma Acuminata

A prospective randomized controlled study of Mycobacterium Indicus Pranii vaccine, Measles Mumps Rubella vaccine and Vitamin D3 in extragenital cutaneous warts

Contact Info

Product

Resources

About